# Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

> **NCT05776004** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eagle Pharmaceuticals, Inc.** · enrollment: 276 (estimated)

## Conditions studied

- Pneumonia, Bacterial

## Interventions

- **DRUG:** CAL02
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05776004
- **Lead sponsor:** Eagle Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-22
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-09-07
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776004, "Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05776004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*